Drug Trial Radar · NCT03331198
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Nov 27, 2017
Primary completion
Nov 26, 2027
Study completion Nov 26, 2027
Sponsor
- Lead sponsor
- Juno Therapeutics, a Subsidiary of CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Small Lymphocytic
Interventions
JCAR017 (lisocabtagene maraleucel)Biological
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
JCAR017 (lisocabtagene maraleucel) + ibrutinibBiological
Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
JCAR017 (lisocabtagene maraleucel) + venetoclaxBiological
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 JCAR017 monotherapy arm: adverse eventsTime frame: Up to 48 months post treatment
- Phase 1 JCAR017 monotherapy arm: laboratory abnormalitiesTime frame: Up to 48 months post treatment
- Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse eventsTime frame: Up to 48 months post treatment
- Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalitiesTime frame: Up to 48 months post treatment
- Phase 1 JCAR017 and ibrutinib combination dose expansion therapy armTime frame: Through post treatment up to Month 48
- Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: adverse eventsTime frame: Up to 48 months post treatment
- Phase 1 JCAR017 and venetoclax combination dose escalation therapy arm: laboratory abnormalitiesTime frame: Up to 48 months post treatment
- Phase 1 JCAR017 and venetoclax combination dose expansion therapy armTime frame: Through post treatment up to Month 48
- Phase 2 JCAR017 monotherapy expansion armTime frame: Through post treatment up to Month 48
- Phase 2 JCAR017 Double exposed monotherapy expansion arm: overall response rate (ORR)Time frame: Up to approximately 24 months
Locations
84 sites in 2 countries. Site status is shown where the registry gives one.
Local Institution - 0006
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Banner MD Anderson Cancer Center
Gilbert, Arizona
Local Institution - 0043
Gilbert, Arizona
City of Hope
Duarte, California
Local Institution - 0007
Duarte, California
Local Institution - 0025
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
Local Institution - 0059
Los Angeles, California
University of California, Los Angeles
Los Angeles, California
Local Institution - 0010
San Francisco, California
University of California, San Francisco
San Francisco, California
Local Institution - 0111
Denver, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Local Institution - 0085
Washington D.C., District of Columbia
Local Institution - 0080
Jacksonville, Florida
Mayo Clinic
Jacksonville, Florida
Local Institution - 0104
Atlanta, Georgia
Local Institution - 0019
Atlanta, Georgia
The Blood and Marrow Transplant Group of Georgia (BMTGA)
Atlanta, Georgia
Local Institution - 0003
Chicago, Illinois
Northwestern University
Chicago, Illinois
Local Institution - 0016
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
Local Institution - 0105
Indianapolis, Indiana
Local Institution - 0107
Wichita, Kansas
Local Institution - 0064
Louisville, Kentucky
Local Institution - 0027
New Orleans, Louisiana
Local Institution - 0005
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Local Institution - 0015
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Local Institution - 0084
Ann Arbor, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Local Institution - 0062
Detroit, Michigan
Local Institution - 0109
Detroit, Michigan
Local Institution - 0054
Rochester, Minnesota
Mayo Clinic
Rochester, Minnesota
Local Institution - 0008
Omaha, Nebraska
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.